United States· US:0003-7125_1150d07b-4d33-4285-a242-1ecf12ed5a4c
OPDUALAG
A medicinal product containing nivolumab and relatlimab-rmbw, registered in United States by E.R. Squibb & Sons, L.L.C..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- nivolumab and relatlimab-rmbw
- Manufacturer
- E.R. Squibb & Sons, L.L.C.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 3, 2026
Packs & prices · 1
- ndc1100037125111 VIAL, SINGLE-DOSE in 1 CARTON (0003-7125-11) / 20 mL in 1 VIAL, SINGLE-DOSE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a9011004-0e37-4a11-b8e8-ebd0a6626cd9 GET /v1/drugs/a9011004-0e37-4a11-b8e8-ebd0a6626cd9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"productid": "0003-7125_1150d07b-4d33-4285-a242-1ecf12ed5a4c",
"productndc": "0003-7125",
"dosage_form": "INJECTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "NIVOLUMAB; RELATLIMAB",
"proprietary_name": "OPDUALAG",
"active_ingred_unit": "mg/mL; mg/mL",
"application_number": "BLA761234",
"marketing_category": "BLA",
"nonproprietary_name": "nivolumab and relatlimab-rmbw",
"start_marketing_date": "20220318",
"active_numerator_strength": "12; 4"
}See everything about nivolumab and relatlimab-rmbw.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.